Evidence map›Paper›PMID 41974665›Full record

ArticleCell death discovery2026

NT5DC2 inhibits ferroptosis by stabilizing ACSL3 in bladder cancer.

Shaorui Niu, Pang Yang, Yuyang Yao, Xiaofeng Tang, Jun Yang, Feifei Zhang, Kangming Chen, Chengli Jiang, Yuhao Zhou, Wei Bai and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shaorui Niu *Jiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Pang Yang *Department of Urology, The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuyang Yao *Jiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Xiaofeng TangJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jun YangJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Feifei ZhangJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Kangming ChenJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Chengli JiangJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuhao ZhouJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Wei BaiJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Liping LiJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Yuntong ZhouZhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
Xiao-Bin LvJiangxi Key Laboratory of Oncology, The Central Lab of The First Hospital of Nanchang, The Third Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. nclvxiaobin@ncu.edu.cn.ORCID http://orcid.org/0009-0001-1322-6768

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82360472Natural Science Foundation of Jiangxi Province (Jiangxi Province Natural Science Foundation) 20232BAB20609Science and Technology Bureau of Nanchang City (Nanchang Municipal Science and Technology Bureau) 2021-156Science and Technology Bureau of Nanchang City (Nanchang Municipal Science and Technology Bureau) 2022-KJZC-008
6 · The paper itself

Abstract

Ferroptosis, a form of regulated cell death, plays a pivotal role in the development and treatment of cancer because of its impact on tumor cell proliferation, differentiation, and resistance to chemotherapy. NT5DC2, a gene associated with ferroptosis, has been identified as a key facilitator of cellular proliferation and metastasis in several cancers. In this study, we found that NT5DC2 is highly expressed in bladder cancer tissues compared with normal tissues and that its expression is correlated with the poor prognosis of bladder cancer patients. Functionally, we demonstrated that NT5DC2 suppresses ferroptosis in bladder cancer cells and promotes malignant tumor progression. Mechanistically, NT5DC2 interacts with ACSL3 and hampers its ubiquitination, thereby improving the stability of ACSL3, a crucial ferroptosis suppressing protein induced by oleic acid in lymph nodes. In addition, rescue assay results indicated that ACSL3 mediated the roles of NT5DC2 in suppressing ferroptosis of bladder cancer cells. Furthermore, we found that the upregulation of ACSL3 by oleic acid treatment was mediated by NT5DC2 as manifested by the observation that silencing of NT5DC2 abrogates this regulatory effect of oleic acid treatment. Collectively, our findings suggest that NT5DC2/ACSL3 plays a critical role in bladder cancer progression and ferroptosis regulation, suggesting that NT5DC2/ACSL3 is a potential therapeutic target for bladder cancer treatment.

Identifiers

PMID41974665
PMCPMC13184144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.